SCHEMBL4129057

SCHEMBL4129057

CCN(CC)CCN(CCNC(=O)Nc1cccc(F)c1)C(=O)Nc1cccc(F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.46
▸ MEN1 O00255 4/20 0.46
▸ MAPT P10636 4/20 0.46
▸ MARS1 P56192 1/20 0.46
▸ MCHR1 Q99705 3/20 0.44
▸ MTOR P42345 1/20 0.44
▸ RAB9A P51151 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ BCHE P06276 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ CA12 O43570 1/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ CA9 Q16790 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ AURKA O14965 1/20 0.42
▸ PAK4 O96013 1/20 0.42
▸ ABL1 P00519 1/20 0.42
▸ NTRK1 P04629 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4107284 0.86 MCHR1 (0.59) KMT2AMEN1MAPTMCHR1RAB9A
SCHEMBL4116381 0.82 MCHR1 (0.58) KMT2AMEN1MAPTMCHR1MTOR
SCHEMBL4115328 0.79 MCHR1 (0.61) KMT2AMEN1MAPTMCHR1MTOR
SCHEMBL4113667 0.79 MEN1 (0.51) KMT2AMEN1MAPTMCHR1POLB
SCHEMBL4118978 0.79 GAA (0.59) KMT2AMEN1MAPTMCHR1RAB9A
SCHEMBL4115134 0.78 MEN1 (0.53) KMT2AMEN1MCHR1POLB
SCHEMBL4118376 0.78 MCHR1 (0.66) KMT2AMEN1MCHR1MTORPOLB
SCHEMBL23413004 0.75 MEN1 (0.58) KMT2AMEN1MAPTMCHR1RAB9A
SCHEMBL30093030 0.75 MEN1 (0.58) KMT2AMEN1MAPTMCHR1RAB9A
SCHEMBL4106239 0.74 MCHR1 (0.52) KMT2AMEN1MCHR1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118330-A1 Diurea derivatives ACTIVE BIOTECH AB (SE) 2009-05-07 — — US claimed
EP-1711175-A1 DIUREA DERIVATIVES Active Biotech AB (SE) 2006-10-18 — — EP claimed
WO-2005074919-A1 DIUREA DERIVATIVES ACTIVE BIOTECH AB (SE) 2005-08-18 — — WO claimed
US-20090118330-A1 Diurea derivatives ACTIVE BIOTECH AB (SE) 2009-05-07 — — US disclosed
EP-1711175-A1 DIUREA DERIVATIVES Active Biotech AB (SE) 2006-10-18 — — EP disclosed
WO-2005074919-A1 DIUREA DERIVATIVES ACTIVE BIOTECH AB (SE) 2005-08-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118330-A1 Diurea derivatives IL2, CASP2, MAVS KMT2A 2720/4885MEN1 4167/4885MAPT 1996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback